ContraFect Corp: Business Overview, Financials & Competitive Analysis
ContraFect Corp scores 2/10 on the AskCyborg Cyborg Score (Challenged). Once-promising lysin platform failed to achieve clinical-stage funding sustainability, resulting in liquidation. The company entered bankruptcy liquidation in December 2023, indicating failed clinical development, regulatory setbacks, or funding challenges that prevented commercialization. While the scientific platform was novel, execution and capitalization proved insufficient.
What is ContraFect Corp's industry? ContraFect Corp (contrafect.com) operates in Stem Cell Therapy. AskCyborg classifies ContraFect Corp under Stem Cell Therapy in its company registry.
ContraFect Corp was a clinical-stage biotechnology company focused on developing novel therapeutics for drug-resistant, life-threatening infectious diseases. The company pioneered direct lytic agents (lysins and amuri...
Cyborg Score thesis
Once-promising lysin platform failed to achieve clinical-stage funding sustainability, resulting in...
Read the full analyst-debate transcript →Get the Latest ContraFect Corp Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeContraFect Corp Overview
Pro stress-test →ContraFect Corp was a clinical-stage biotechnology company focused on developing novel therapeutics for drug-resistant, life-threatening infectious diseases. The company pioneered direct lytic agents (lysins and amurin peptides) as new medical modalities to combat antibiotic-resistant pathogens. However, the company filed for Chapter 7 liquidation in December 2023.
Strategic Profile
Pro stress-test →ContraFect's innovation centered on bacteriophage-derived lysins targeting conserved bacterial regions resistant to mutation, with lead candidate exebacase (CF-301) for prosthetic joint infections and CF-370 for gram-negative pathogens. The company held a license agreement with The Rockefeller University for gram-negative lysin research. Operations ceased following liquidation filing.
Competitive Landscape
Pro stress-test →ContraFect competed in the antibiotic resistance therapeutics space against traditional small-molecule antibiotic developers, monoclonal antibody platforms (Regeneron, GSK), and other novel modality companies (phage therapy platforms, antimicrobial peptides). Its differentiation through bacteriophage lysins offered a novel mechanism but failed to achieve regulatory or commercial success.
Industry Context
ContraFect Corp operates in Stem Cell Therapy.
Key facts
Founded: 2008 · Headquarters: Yonkers, US · Employees: 23 · Revenue: N/A · Market cap: N/A